MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

MDT

89.67

-0.09%↓

VEEV

276.66

-1.93%↓

A

116.42

+2.59%↑

WBA

11.51

-0.09%↓

HQY

100.13

+2.61%↑

Search

Design Therapeutics Inc

Затворен

3.96 -4.35

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.93

Максимум

4.27

Ключови измерители

By Trading Economics

Приходи

-4.1M

-18M

Служители

56

EBITDA

-3.7M

-20M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+116.84% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-37M

227M

Предишно отваряне

8.31

Предишно затваряне

3.96

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Design Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.07.2025 г., 23:34 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17.07.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17.07.2025 г., 21:04 ч. UTC

Значими двигатели на пазара
Придобивния, сливания и поглъщания

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17.07.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17.07.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17.07.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17.07.2025 г., 22:46 ч. UTC

Придобивния, сливания и поглъщания

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17.07.2025 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17.07.2025 г., 22:30 ч. UTC

Пазарно говорене
Печалби

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

17.07.2025 г., 22:20 ч. UTC

Пазарно говорене
Печалби

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17.07.2025 г., 22:04 ч. UTC

Пазарно говорене
Печалби

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17.07.2025 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17.07.2025 г., 21:58 ч. UTC

Пазарно говорене
Печалби

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17.07.2025 г., 21:57 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:47 ч. UTC

Печалби

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17.07.2025 г., 21:38 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17.07.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 21:05 ч. UTC

Печалби

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17.07.2025 г., 21:04 ч. UTC

Придобивния, сливания и поглъщания

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17.07.2025 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17.07.2025 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

17.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Design Therapeutics Inc Прогноза

Ценова цел

By TipRanks

116.84% нагоре

12-месечна прогноза

Среден 8.5 USD  116.84%

Висок 12 USD

Нисък 5 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Design Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

1

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

3.26 / 3.63Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.